Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.
about
Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemGeneralized enrichment analysis improves the detection of adverse drug events from the biomedical literatureData mining of the public version of the FDA Adverse Event Reporting SystemHepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre.Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(®).Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®.Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by AgeTwo cheers or three for treatment guidelines? Nudging prescribers in right directions.Drug-Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms.Safety profile of enantiomers vs. racemic mixtures: it's the same?Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes.Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase.Computational Drug Repositioning Using Continuous Self-Controlled Case SeriesIdentification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database.An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database.Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.Ibuprofen-associated hypothermia in children: analysis of the Italian spontaneous reporting database.Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase.Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.Shift in energy metabolism caused by glucocorticoids enhances the effect of cytotoxic anti-cancer drugs against acute lymphoblastic leukemia cells.Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase® , the WHO pharmacovigilance database.Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR.Statins and diabetes: is there any difference between the different statins?SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.Detection of signals of abuse and dependence applying disproportionality analysis.Off-label use of nicardipine as tocolytic and acute pulmonary oedema: a post-marketing analysis of adverse drug reaction reports in EudraVigilance.A comparative study of QT prolongation with serotonin reuptake inhibitors.Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.Three-Component Mixture Model-Based Adverse Drug Event Signal Detection for the Adverse Event Reporting System
P2860
Q28257188-7FC1D842-1DF4-4097-B8AE-D474983E0656Q28829259-F98A3623-EC60-4262-85B3-9A33CA58FA79Q30651235-41023E19-742F-4940-B3E1-C352F8C5AD12Q30887490-8EE5C333-55D6-4D4E-9AFB-AF770CD695CBQ31056264-E7D1CB63-FE95-432D-A0B5-6295FAFD4500Q33425628-276E3E32-8E6C-4D51-8C91-B9BA77BCFCBBQ35475000-9A414EE6-301F-44C7-A07C-699CF19F4A70Q35629729-DB7889DD-9DAB-495B-974A-957CD053BF68Q35809210-95997DF8-346C-4D62-A691-967DA981CDE6Q36390295-665799A0-3C4F-4399-B2F1-DE0D63B591E9Q38416814-32AE03EE-C93E-4303-B6F8-72F37B91B10EQ38661018-C38DF99F-5ABF-4475-9507-E5219CBEE3D0Q38895303-748EA6BB-F664-4E72-8C11-D3C4013CBDFBQ39014995-4FAE8C04-6589-4D30-872C-DF1B930C5D8CQ39077216-C2D2164F-4A9C-4881-BEB9-1AF6CFB61DA1Q39336646-CD221F4F-8B43-411D-AE95-1447C3C47119Q39652499-77977508-AE40-4ECD-9BB0-6E8344202C25Q39875505-EE32C290-8AE5-439A-AC7E-E7FA14AA8E43Q40096669-378E6B44-DB34-46C6-BCAA-54C14ED668C1Q40561965-3AB7E9EF-CC93-41E5-BE70-442F3A69B994Q40701817-EC558DDE-CD66-4C1B-8101-9D2BE22E7D1AQ46246675-0189220F-3100-4ADB-8C6D-37197B0B653EQ47779429-9AE3E62A-5EC0-4D4E-ADCB-C504F43E4FBAQ47864318-4BA8630C-5819-4D31-81D2-2EB62BB3B101Q48261639-8C85C146-66F3-43BC-BA46-F12E25519E0AQ48291193-04BE4073-263A-4C9B-BCBC-438AB13FF1EFQ50315312-F27EA1A7-7E5F-4A80-8807-64E9801B498CQ51136025-E1C4F1A2-9DE2-49F1-84B3-5F3B79CBD225Q51265568-689B2B35-0CD7-4C0A-89FC-968050760812Q53554026-DABE4CD7-8EB8-4065-990F-4229263E0C3BQ53811350-81A67815-FFB8-48C7-BC71-317AA41331FDQ54420490-E5CC0AB6-7DAD-47C9-807A-BC83B7BEC36AQ58792611-608BE8CD-5920-4603-BE19-F46BE00D285F
P2860
Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Benefits and strengths of the ...... a pharmacovigilance database.
@ast
Benefits and strengths of the ...... a pharmacovigilance database.
@en
type
label
Benefits and strengths of the ...... a pharmacovigilance database.
@ast
Benefits and strengths of the ...... a pharmacovigilance database.
@en
prefLabel
Benefits and strengths of the ...... a pharmacovigilance database.
@ast
Benefits and strengths of the ...... a pharmacovigilance database.
@en
P2860
P1476
Benefits and strengths of the ...... a pharmacovigilance database.
@en
P2093
Agnès Sommet
Haleh Bagheri
P2860
P304
P356
10.1111/J.1365-2125.2011.04037.X
P407
P577
2011-12-01T00:00:00Z